Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock

Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of US$2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from the offering were US$200.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.

Latham & Watkins LLP represented the underwriters in the transaction with a corporate team led by Orange County/Bay Area partner Shayne Kennedy, with associates Greg Van Buiten, Kennedy Holmes, and Tony Noh. Advice was also provided on FDA matters by Washington, D.C. counsel Chad Jennings, with associate Evan Miller; on healthcare matters by Bay Area partner Betty Pang; on intellectual property matters by San Diego counsel Darryl Steensma, with associates Kristina Funahashi and Dylan O’Connor; on data privacy matters by Bay Area partner Heather Deixler, with associate Chad Leiper; and on tax matters by Bay Area partner Grace Lee, with associate Tessa Young.